Aquestive Therapeutics, Inc.
NASDAQ:AQSTDrug Manufacturers - Specialty & Generic
+$0.23 today
- Market cap
- $475.10M
- Beta
- 1.45
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.56
Volume 1.80M
Average 1.51M
AQST Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Aquestive Therapeutics, Inc.NASDAQ: AQST
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 61.3% from a year ago
Cash & equivalents stood at $110.73M at the end of Q1 FY2026, up 61.3% from a year earlier and down 8.6% from the prior quarter. Over 3 fiscal years it compounded at +64.4% a year.
Context
- Cash & equivalents amounted to 78.5% of total assets at the end of Q1 FY2026, up 11.3 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +61.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 121.17M USD
- Year-over-year change
- +69.4%
- 4-year CAGR
- +44.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 121.17M | +69.4% |
| FY2024 | 2024-12-31 | 71.55M | +199.7% |
| FY2023 | 2023-12-31 | 23.87M | -12.5% |
| FY2022 | 2022-12-31 | 27.27M | -2.7% |
| FY2021 | 2021-12-31 | 28.02M | — |
Cash & Equivalents vs competitors
How AQST compares with its peers on the latest reported figures
- AQST's Mar 2026 cash & equivalents of $110.73M is the 6th highest of the 10 companies compared; the peer median is $111.75M.
- Its year-over-year change of +61.3% is the 4th highest of 10, against a peer median of +24.4%.
- Cash & equivalents amounts to 78.5% of total assets for AQST, versus a peer median of 15.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $631.31M | +2.4% | +56.4% | 14.2% | |
| Mar 2026 | $268.65M | +179.3% | +13.1% | 16.3% | |
| Jun 2026 | $179.95M | +24.4% | +11.3% | 12.6% | |
| Mar 2026 | $171.17M | -6.4% | +2.9% | 10.4% | |
| Mar 2026 | $111.75M | +91.2% | -3.1% | 28.5% | |
| Mar 2026 | $110.73M | +61.3% | +64.4% | 78.5% | |
| Mar 2026 | $95.6M | +156.0% | -1.6% | 34.3% | |
| Mar 2026 | $54.03M | -51.7% | -14.3% | 12.5% | |
| Mar 2026 | $27.22M | +29.2% | -9.0% | 29.7% | |
| Mar 2026 | $11.01M | -27.1% | -16.6% | 15.5% | |
| Peer median (excluding AQST) | $111.75M | +24.4% | -1.6% | 15.5% | |
Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 28.02M | 27.27M | 23.87M | 71.55M | 121.17M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 12.12M | 4.7M | 8.47M | 7.34M | 17.76M |
| Inventory | 4.04M | 5.78M | 6.77M | 6.04M | 6.17M |
| Other Current Assets | 0 | 2.13M | 1.85M | 3.29M | 4.17M |
| Total Current Assets | 47.26M | 39.89M | 40.97M | 88.22M | 149.27M |
| Property, Plant & Equipment (Net) | 7.78M | 9.3M | 9.74M | 8.98M | 8.51M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 51K | 1.44M | 1.28M | 0 | 0 |
| Long-term Investments | 6M | 0 | 4M | 3M | 2M |
| Tax Assets | (6M) | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 6.9M | 6.45M | 1.44M | 1.22M | 642K |
| Total Non-current Assets | 14.73M | 17.18M | 16.45M | 13.2M | 11.16M |
| Total Assets | 61.99M | 57.07M | 57.42M | 101.42M | 160.43M |
| Account Payables | 8.31M | 9.95M | 8.93M | 10.29M | 29.86M |
| Short-term Debt | 2.03M | 18.7M | 22K | 26K | 11.63M |
| Tax Payables | 349K | 322K | 337K | 365K | 0 |
| Deferred Revenue | 765K | 1.51M | 1.55M | 1.05M | 1.09M |
| Other Current Liabilities | 7.19M | 7.54M | 5.12M | 1M | 1.32M |
| Total Current Liabilities | 21.96M | 39.53M | 18.31M | 18.87M | 47.61M |
| Long-term Debt | 51.55M | 33.45M | 27.51M | 32.5M | 115.48M |
| Deferred Tax Liabilities | 59.06M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 7.12M | 31.42M | 32.35M | 20.01M | 19.39M |
| Other Non-current Liabilities | 2.49M | 66.15M | 80.35M | 85.24M | 7.27M |
| Total Non-current Liabilities | 122.16M | 136.1M | 145.6M | 142.72M | 146.48M |
| Total Liabilities | 144.13M | 175.62M | 163.91M | 161.58M | 194.09M |
| Common Stock | 41K | 55K | 69K | 91K | 122K |
| Retained Earnings | (256.8M) | (311.21M) | (319.08M) | (363.21M) | (447M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (82.13M) | (118.55M) | (106.49M) | (60.16M) | (33.66M) |
| Total Debt | 56.42M | 57.49M | 33.32M | 38M | 131.45M |
| Net Debt | 28.4M | 30.22M | 9.45M | (33.54M) | 10.28M |
Aquestive Therapeutics, Inc.
NASDAQ:AQST
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.